Crohns Disease News
|
|
   
|
|
Crohns Disease News Archive14-Jan-2007Research & Markets: One of UCB´s biggest-selling Products, Keppra, Achieved Sales Growth of 34% (wallstreet:online AG) Research and Markets (http://www.researchandmarkets.com/reports/c47159) has announced the addition Research and Markets : The Battle between Cimzia and Humira Will Depend On Efficacy, Convenience and Cost for ... (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of Commercial and Pipeline Insight: Inflammatory Bowel Disease - Competition Increases for the Biologics to their offering. Elan, Biogen Idec submit Tysabri for Crohn's (Pharmaceutical Business Review) Elan and Biogen Idec have submitted a biologics license application to the FDA seeking approval to market Tysabri in the US as a treatment for Crohns disease. Celiac disease is the great masquerader in digestive disorders (Savannah Morning News) Q. Hello, Dr. C. My Name is Jeanne and I am an occupational health nurse. I see employees on a daily basis complaining of digestive disturbances. Many of them have chronic abdominal pains, periodic episodes of diarrhea or constipation, and generally do not feel well. Some have been seen by gastroenterologists and have been given the diagnosis of irritable bowel syndrome. In my own case, I had ... Research & Markets: One of UCB's biggest-selling Products, Keppra, Achieved Sales Growth of 34% (Business Wire via Yahoo! Finance) DUBLIN, Ireland----Research and Markets has announced the addition of the Espicom Business Intelligence Ltd report: UCB Prospects to 2010 to their offering.
Back to Crohns Disease News Archive
|
|